Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Active, not recruiting · NCT03321643 · Registry updated 2026-06-11

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma	B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Richter transformation, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm	Active, not recruiting	Phase 1	2026-06-11		NCT03321643

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
National Cancer Institute (NCI)	3015

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
City of Hope Comprehensive Cancer Center	Duarte	United States	263
Emory University Hospital/Winship Cancer Institute	Atlanta	United States	299
UC San Diego Moores Cancer Center	La Jolla	United States	199
University of California Davis Comprehensive Cancer Center	Sacramento	United States	299